TCGA-DQ-5625-01A-01R-1873-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.258675799
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.620
- MYOGENESIS+0.560
- ALLOGRAFT_REJECTION+0.500
- IL6_JAK_STAT3_SIGNALING+0.440
- INFLAMMATORY_RESPONSE+0.380
- TNFA_SIGNALING_VIA_NFKB+0.380
- KRAS_SIGNALING_UP+0.340
- COMPLEMENT+0.310
- TGF_BETA_SIGNALING+0.310
Top 10 suppressed
- MYC_TARGETS_V2-0.570
- E2F_TARGETS-0.480
- G2M_CHECKPOINT-0.380
- MYC_TARGETS_V1-0.350
- MITOTIC_SPINDLE-0.280
- WNT_BETA_CATENIN_SIGNALING-0.260
- UNFOLDED_PROTEIN_RESPONSE-0.230
- MTORC1_SIGNALING-0.170
- GLYCOLYSIS-0.160
- DNA_REPAIR-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_BC936YNZ | pilocytic astrocytoma | — | 0.891 |
| 2 | BS_KX6J8TRK | pilocytic astrocytoma | — | 0.890 |
| 3 | TCGA-DQ-5630-01A-01R-1873-07 | — | — | 0.878 |
| 4 | b1dde645-b48d-44e0-9fe0-2af02470ffb5 | — | — | 0.876 |
| 5 | BS_Z0AVVB1V | pilocytic astrocytoma | — | 0.876 |
| 6 | BS_7Z93ZYMS | pilocytic astrocytoma | — | 0.869 |
| 7 | BS_V3REENH9 | pilocytic astrocytoma | — | 0.866 |
| 8 | BS_MY9D8XZ1 | pilocytic astrocytoma | — | 0.860 |
| 9 | BS_GWCRMKE6 | pilocytic astrocytoma | — | 0.858 |
| 10 | TCGA-CQ-5325-01A-01R-1686-07 | — | — | 0.856 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.620 | Idelalisib | — uncovered |
| MYOGENESIS | 0.560 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.240 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |